bioRxivCancer BiologyPreprint
The therapeutic effects of intratumoral injection of IL12IL2GMCSF fusion protein on canine tumors
X. Du, B. Zhang, F. Hu, C. Xie, H. Tian, Q. Gu, H. Gong, X. Bai, J. Zhang
Abstract
Regulating the immune system through tumor immunotherapy to defeat tumors is currently one of the most popular methods of tumor treatment. We previously found that the combinations of IL12, IL2 and GMCSF has superior antitumor activities. In this study, IL12IL2GMCSF fusion protein was produced from 293 cells transduced by expression lentiviral vector. IL12IL2GMCSF fusion protein was injected into canine tumors, and the efficacy was monitored to evaluate the potential of tumor immunotherapy. In 14 canines injected with IL12IL2GMCSF protein, 6 had a complete response (CR), 7 had a partial response (PR), and 1 had stable disease (SD). IL12IL2GMCSF fusion protein has great anti-tumor potential. Intratumoral injection of IL12IL2GMCSF can effectively treat tumors without severe adverse effects. It provides a promising immune therapeutics in canine cancers.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Administration of fusion cytokines induces tumor regression and systemic antitumor immunity
- In situ administration of cytokine combinations induces tumor regression
- Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regs
Gregory W. Ho, Alicia Santos, … Steven Fiering·Scientific ReportsPeer-reviewed·Jul 8, 2025
- The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors
- Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs
J. A. Stinson, M. M. P. Barbosa, … T. M. Fan·bioRxiv·Feb 12, 2024
- Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity
E. K. Leonard, J. Tomala, … J. B. Spangler·bioRxiv·May 3, 2023